Table 2.
Clinical studies with TNKase in STEMI
| Trial (year) | Patients | Comparison | Main findings |
|---|---|---|---|
| ASSENT-2 (1999) | 16,949 | TNKase vs rt-PA | TNKase and rt-PA equivalent, ↓ major bleeding with TNKase |
| ASSENT-3 (2001) | 6,095 | ENOX vs ABX vs UFHa | ENOX and ABX better than UFH |
| ENTIRE-TIMI 23 (2002) | 483 | ENOX vs ABX vs UFHa | ENOX and ABX better than UFH, ↑ bleeding with ABX |
| ASSENT-3-PLUS (2003) | 1,639 | ENOX vs UFHa, pre-hospital delivery | ↓ reinfarction with ENOX, ↑ stroke/intracranial bleed |
| CAPITAL-AMI (2005) | 170 | F-PCIc vs TNKasea | ↓ residual ischemia with F-PCI |
| ASSENT-4 (2006) | 1,667 | F-PCIc vs P-PCIb | ↑ death/ischemia/bleeding in the F-PCI group |
| WEST (2006) | 304 | TNKase vs F-PCIc vs P-PCI | TNKase and F-PCI comparable to P-PCI |
| GRACIA-2 (2007) | 212 | TNKased vs P-PCI | ↑ reperfusion with TNKased Similar ventricular damage |
a
All patients in the trial received TNKase.
b
P-PCI: Primary angioplasty.
c
F-PCI: Primary angioplasty, facilitated by TNKase.
d
TNKase followed by routine angioplasty within 3–12 hours (“pharmaco-invasive” approach).